Literature DB >> 10977426

Patient compliance in depression. Based on a presentation by James Jefferson, MD.

.   

Abstract

Results of a study of comorbidity reveal that Americans have a 10.3% 1-year risk and a 17.1% life-time risk of experiencing a major depressive disorder. Identification and treatment of depression are vital to the outcome of the illness, whose course is characterized by 5 phases: response, remission, relapse, recovery, and recurrence. Treatment must be seen as a 2-fold process involving continuation and maintenance of therapy to avoid relapses, which become more and more frequent after each depressive episode. Ensuring that patients comply with their medication regimens is a major challenge for physicians and requires patient understanding and cooperation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10977426

Source DB:  PubMed          Journal:  Am J Manag Care        ISSN: 1088-0224            Impact factor:   2.229


  2 in total

1.  Comparing treatment persistence, healthcare resource utilization, and costs in adult patients with major depressive disorder treated with escitalopram or citalopram.

Authors:  Eric Q Wu; Paul E Greenberg; Rym Ben-Hamadi; Andrew P Yu; Elaine H Yang; M Haim Erder
Journal:  Am Health Drug Benefits       Date:  2011-03

2.  Antidepressant-related adverse effects impacting treatment compliance: Results of a patient survey.

Authors:  Adam Keller Ashton; Brenda D Jamerson; Wendy L Weinstein; Christine Wagoner
Journal:  Curr Ther Res Clin Exp       Date:  2005-03
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.